Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Adaptimmune Therapeutics PLC changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 68 | 1 | 69 | +2 |
| Shares | 113.9M | 90.0K | 114.0M | +174.5K (+0.2%) |
| Value | $122.4M | $97.0K | $166.3M | +$44.0M (+36.0%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Lazard Asset Management LLC | 98,590 | $143.0K | 0.00% |
| Marshall Wace, LLP | 89,171 | $130.2K | 0.00% |
| Kapitalo Investimentos Ltda | 36,400 | $53.1K | 0.04% |
| Arrowstreet Capital, Limited Partnership | 32,586 | $48.0K | 0.00% |
| Prosperity Wealth Management, Inc. | 30,620 | $44.7K | 0.04% |
| Susquehanna International Group, LLP | 28,126 | $41.1K | 0.00% |
| Qube Research & Technologies Ltd | 27,001 | $39.4K | 0.00% |
| Caxton Associates LP | 25,713 | $37.5K | 0.00% |
| Cubist Systematic Strategies, LLC | 22,628 | $33.0K | 0.00% |
| Two Sigma Investments, LP | 22,600 | $33.0K | 0.00% |
| State of Tennessee, Treasury Department | 13,100 | $19.0K | 0.00% |
| Douglas Lane & Associates, LLC | 13,000 | $19.0K | 0.00% |
| StoneX Group Inc. | 11,431 | $16.7K | 0.00% |
| Advisory Services Network, LLC | 325 | $475 | 0.00% |
| GWM Advisors LLC | 900 | $1 | 0.00% |
Sold out (13)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| ExodusPoint Capital Management, LP | 370,288 | $398.0K |
| Barclays PLC | 340,068 | $366.0K |
| WS Management LLLP | 115,602 | $124.0K |
| Alps Advisors Inc | 88,339 | $95.0K |
| Captrust Financial Advisors | 19,622 | $21.0K |
| RFG Advisory, LLC | 10,000 | $21.0K |
| US Bancorp | 16,049 | $18.0K |
| Creative Planning | 12,878 | $14.0K |
| Running Point Capital Advisors, LLC | 10,000 | $11.0K |
| Lindbrook Capital, LLC | 3,084 | $3.00K |
| Quadrant Capital Group LLC | 1,046 | $1.00K |
| Aquatic Capital Management LLC | 1,100 | $1.00K |
| Harbour Investments, Inc. | 200 | $0 |
Not filed for Q4 2022 yet (1)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| ACT Capital Management, LLC | 90,000 | $97.0K |